Literature DB >> 32215758

Trends in Surgical Axillary Management in Early Stage Breast Cancer in Elderly Women: Continued Over-Treatment.

Raphael J Louie1, Charles E Gaber2,3, Paula D Strassle2,3, Kristalyn K Gallagher1, Stephanie M Downs-Canner1, David W Ollila4.   

Abstract

INTRODUCTION: In the past two decades, three prospective randomized trials demonstrated that elderly women with early stage hormone positive breast cancer had equivalent disease-specific mortality regardless of axillary surgery. In 2016, the Choosing Wisely campaign encouraged patients and providers to reconsider the role of axillary surgery in this population. We sought to identify factors that contribute to adopting non-operative management of the axilla in these patients.
MATERIALS AND METHODS: We performed a retrospective analysis of women ≥ 70 years old with cT1/T2, hormone positive invasive ductal carcinoma who underwent partial or total mastectomy, with/without axillary surgery, and did not receive adjuvant chemotherapy from the National Cancer Database from 2004 to 2015. We used multivariable log-binomial regression to model the risk of undergoing axillary surgery across region, care setting, and Charlson-Deyo scores, and analyzed temporal trends using Poisson regression. From 2004 to 2015, 87,342 of 99,940 women who met inclusion criteria (83%) had axillary surgery. Over time, axillary surgery increased from 78% to 88% (p < 0.001). This rise was consistent across region (p = 0.81) and care setting (p = 0.09), but flattened as age increased (p < 0.001). Omitting axillary surgery was more likely in patients treated in New England (RR 0.88, 95% CI 0.86, 0.89) and patients ≥ 85 (RR 0.66, 95% CI 0.65, 0.67).
CONCLUSIONS: Axillary surgery continues to be the preferred option of axillary management in elderly women with early stage, clinically node negative, hormone-positive, invasive breast cancer despite no survival benefit. Identifying factors to improve patient selection and dissemination of current recommendations can improve adoption of current evidence on axillary surgery in the elderly.

Entities:  

Mesh:

Year:  2020        PMID: 32215758      PMCID: PMC7415703          DOI: 10.1245/s10434-020-08388-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  22 in total

1.  Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age.

Authors:  Jennifer K Plichta; Samantha M Thomas; Rebecca Vernon; Oluwadamilola M Fayanju; Laura H Rosenberger; Terry Hyslop; E Shelley Hwang; Rachel A Greenup
Journal:  Breast Cancer Res Treat       Date:  2020-01-24       Impact factor: 4.872

2.  Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.

Authors:  Carl-Magnus Rudenstam; David Zahrieh; John F Forbes; Diana Crivellari; Stig B Holmberg; Piercarlo Rey; David Dent; Ian Campbell; Jürg Bernhard; Karen N Price; Monica Castiglione-Gertsch; Aron Goldhirsch; Richard D Gelber; Alan S Coates
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

3.  Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70 Years or Older with Hormone Receptor-Positive Breast Cancer?

Authors:  Judy C Boughey; Bruce G Haffty; Elizabeth B Habermann; Tanya L Hoskin; Matthew P Goetz
Journal:  Ann Surg Oncol       Date:  2017-01-04       Impact factor: 5.344

4.  Cancer recurrence: an important but missing variable in national cancer registries.

Authors:  Haejin In; Karl Y Bilimoria; Andrew K Stewart; Kristen E Wroblewski; Mitchell C Posner; Mark S Talamonti; David P Winchester
Journal:  Ann Surg Oncol       Date:  2014-02-07       Impact factor: 5.344

Review 5.  Shoulder and arm morbidity in sentinel node-negative breast cancer patients: a systematic review.

Authors:  Hanne Verbelen; Nick Gebruers; Fau-Mei Eeckhout; Kim Verlinden; Wiebren Tjalma
Journal:  Breast Cancer Res Treat       Date:  2014-02-05       Impact factor: 4.872

Review 6.  Using the National Cancer Database for Outcomes Research: A Review.

Authors:  Daniel J Boffa; Joshua E Rosen; Katherine Mallin; Ashley Loomis; Greer Gay; Bryan Palis; Kathleen Thoburn; Donna Gress; Daniel P McKellar; Lawrence N Shulman; Matthew A Facktor; David P Winchester
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

7.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

Authors:  Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow
Journal:  JAMA       Date:  2011-02-09       Impact factor: 56.272

8.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Authors:  Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi
Journal:  Lancet Oncol       Date:  2013-03-11       Impact factor: 41.316

9.  Future of cancer incidence in the United States: burdens upon an aging, changing nation.

Authors:  Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2009-04-29       Impact factor: 44.544

10.  Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice.

Authors:  Jessemae L Welsh; Tanya L Hoskin; Courtney N Day; Elizabeth B Habermann; Matthew P Goetz; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2017-08-01       Impact factor: 5.344

View more
  5 in total

1.  Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy.

Authors:  Elaine McKevitt; Rona Cheifetz; Kimberly DeVries; Alison Laws; Rebecca Warburton; Lovedeep Gondara; Caroline Lohrisch; Alan Nichol
Journal:  Ann Surg Oncol       Date:  2021-04-05       Impact factor: 5.344

2.  The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment.

Authors:  Kathleen Iles; Mya L Roberson; Philip Spanheimer; Kristalyn Gallagher; David W Ollila; Paula D Strassle; Stephanie Downs-Canner
Journal:  NPJ Breast Cancer       Date:  2022-03-01

3.  Imaging features of sentinel lymph node mapped by multidetector-row computed tomography lymphography in predicting axillary lymph node metastasis.

Authors:  Xiaochan Ou; Jianbin Zhu; Yaoming Qu; Chengmei Wang; Baiye Wang; Xirui Xu; Yanyu Wang; Haitao Wen; Andong Ma; Xinzi Liu; Xia Zou; Zhibo Wen
Journal:  BMC Med Imaging       Date:  2021-12-15       Impact factor: 1.930

4.  Assessment of Oncologists' Perspectives on Omission of Sentinel Lymph Node Biopsy in Women 70 Years and Older With Early-Stage Hormone Receptor-Positive Breast Cancer.

Authors:  Christina A Minami; Ava F Bryan; Rachel A Freedman; Anna C Revette; Mara A Schonberg; Tari A King; Elizabeth A Mittendorf
Journal:  JAMA Netw Open       Date:  2022-08-01

5.  Neighborhood socioeconomic status and low-value breast cancer care.

Authors:  J C Chen; Yaming Li; James L Fisher; Oindrila Bhattacharyya; Allan Tsung; Samilia Obeng-Gyasi
Journal:  J Surg Oncol       Date:  2022-04-22       Impact factor: 2.885

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.